Loading companies…
Loading companies…
United States · Biotech · Healthtech · Enterprise software
Develops genetically-guided therapy targeting sIL7R to treat autoimmune diseases including RA and lupus
| Announced | Round | Amount | Investors |
|---|---|---|---|
| Seed+ | $1M | Elmstead Partners — Role not disclosedEos BioInnovation — Role not disclosedIndependent Capital — Role not disclosedNewTech Investment Holdings — Role not disclosed |